ArticleDermatology and therapy2026
Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA) is an inflammatory hair loss disorder, which negatively impacts health-related quality of life (HRQoL). This study investigates treatment patterns and HRQoL by AA disease severity.
methodsData were drawn from the Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and patients in the USA from November 2023 to June 2024. Dermatologists reported patient demographics, clinical characteristics, treatment patterns, and mental health. Patients completed AA Symptom Impact Scale, Skindex-16 AA, and Work Productivity and Activity Impact questionnaires. Data were stratified by AA-Investigator Global Assessment (IGA) scores and physician-assessed disease severity.
resultsOverall, 65 physicians reported on 501 patients, of whom 81 self-reported data. In total, 211 patients had severe/very severe AA-IGA-scored AA, of whom 66% received oral Janus kinase and 31% received non-topical corticosteroids. Among 501 patients, 43% had concomitant conditions. Anxiety (74%) and depression (61%) were most prevalent in severe/very severe AA-IGA-scored AA. Patients with severe/very severe AA reported notably high mean (standard deviation) scores on the global AA Symptom Impact Scale (AA-IGA, 3.1 [2.5]; physician-assessed, 3.0 [2.4]), Skindex-16 Emotion subscale (AA-IGA, 59.5 [29.8]; physician-assessed, 59.8 [27.5]) and overall work impairment (AA-IGA, 16.2% [21.4]; physician-assessed, 17.5% [20.2]).
conclusionsThis study showed that AA severity may correlate with HRQoL, highlighting the need for validated severity measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.